过去十年肝细胞癌治疗趋势变化:法国全国数据库分析
该研究基于法国PMIS数据库回顾性分析了2010至2019年所有成年肝细胞癌患者的治疗操作,共纳入34000例患者、68416次治疗操作。结果显示肝细胞癌发病率稳定但年度操作数从4267增至8042,经动脉化疗栓塞是最常进行的技术操作,选择性内放射治疗增幅最大(+475%),经皮热消融成为肝硬化和非肝硬化患者首选的根治性治疗。
要点
- 肝细胞癌年度治疗操作数从2010年4267次增至2019年8042次,发病率稳定。
- 经动脉化疗栓塞是最常进行的技术操作,2010至2015年呈两位数年增长后趋稳。
- 选择性内放射治疗十年增幅最大(+475%),经皮热消融占2019年肝硬化患者根治性治疗的64%。
核心结论
- 微创操作在肝细胞癌管理中地位显著提升,经皮热消融已成为肝细胞癌患者首选的根治性治疗。
- 过去十年肝细胞癌治疗操作总量明显增加,但发病率保持稳定。
研究设计与样本
- 回顾性分析法国医疗信息化系统数据库(PMIS),该数据库包含法国所有医院的出院总结。
主要发现
- 肝细胞癌年操作数从2010年4267次增至2019年8042次,而发病率保持稳定。
- 经动脉化疗栓塞是最常进行的技术操作,2010年1932次增至2015年4085次,2016年后趋于稳定。
- 选择性内放射治疗十年增幅最大(+475%)。
- 经皮肿瘤消融年操作数十年间翻倍以上,2019年占肝硬化患者根治性治疗的64%。
- 外科肿瘤切除十年间增加1.5倍,主要因微创入路大幅增加,而开放切除比例逐步下降。
临床怎么用
- 微创治疗(经皮消融、微创切除、选择性内放射治疗)在肝细胞癌临床实践中应用日益广泛,应重视多学科治疗模式的整合。
- 经皮热消融已成为肝细胞癌根治性治疗的重要选择,尤其适用于肝硬化患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The therapeutic strategies for hepatocellular carcinoma (HCC) have greatly expanded in recent years. However, the actual usage of each of these treatments in clinical routine remains unknown. Here, we analysed the distribution and changes of the main surgical and radiological therapeutic procedures nationwide during the last decade. METHODS: Retrospectively, analysis of the data on all >18-year-old patients with a diagnosis of HCC identified in the French Program for the Medicalization of Information Systems database that contains all discharge summaries from all French hospitals. The number and percentage of the therapeutic procedures performed from January 2010 to December 2019 were extracted. RESULTS: A total of 68,416 therapeutic procedures were performed in 34,000 HCC patients. Whereas HCC incidence remained stable, the annual number of procedures frankly increased over the decade (from 4267 to 8042). Trans-arterial chemoembolization was the most frequently performed technical procedure, with a double-digit annual growth from 2010 (n = 1932) to 2015 (n = 4085), before stabilization from 2016. Selective internal radiation therapy displayed the highest increase in the decade (+475%). Among curative treatments, the annual number of percutaneous tumour ablations more than doubled in 10 years, till representing 64% of curative treatments in cirrhotic patients in 2019. Surgical tumour resections showed a 1.5-fold increase in 10 years, due to the great increase in minimally invasive approaches, whereas the proportion of open resection progressively decreased. CONCLUSION: Minimally invasive procedures have gained major importance in HCC management during the last decade. Percutaneous thermal ablation has emerged as the first curative treatment performed for patients with HCC.
引用
- Cassinotto C, Nogue E, Morell M, et al. Changing trends in hepatocellular carcinoma management: Results from a nationwide database in the last decade. Eur J Cancer. 2021. PMID: 33582392. doi:10.1016/j.ejca.2021.01.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。